Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price reached a new 52-week high during trading on Thursday . The company traded as high as C$0.32 and last traded at C$0.31, with a volume of 982216 shares changing hands. The stock had previously closed at C$0.28.
Hemostemix Trading Up 25.0 %
The company has a market capitalization of C$30.49 million, a P/E ratio of -17.50 and a beta of 0.20. The stock’s fifty day moving average is C$0.12 and its 200 day moving average is C$0.09.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
